NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
SUPN
Indivior Pharmaceuticals Inc
SUPN has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SUPN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Healthy |
SUPN's revenue, profitability and balance sheet are currently healthy, but its cash flow is under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SUPN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.4x | $29.20 | — |
| Current | 8.2x | $29.20 | — |
| Cheap | 18x | $63.68 | +118% |
| Fair | 26x | $91.92 | +215% |
| Expensive | 97x | $347 | +1088% |
Historical ranges are pointers, not guarantees.
SUPN has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SUPN Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
SUPN has the edge over NVO on the outlook, with more favorable earnings expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SUPN on earnings, with more consistent year-over-year improvement.
SUPN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.97 | +11% |
| Q3 2026 | $3.58 | +175% |
| Q2 2026 | $2.79 | +179% |
| Q1 2026 | $1.95 | +1293% |
| Q4 2025 | $1.64 | +681% |
| Q3 2025 | $1.30 | +829% |
| Q2 2025 | $1.00 | +$1.83 |
| Q1 2025 | $0.14 | -18% |
| Q4 2024 | $0.21 | +425% |
SUPN earned $3.58 per share over the past year, up 175% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SUPN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
SUPN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $356M | +13% |
| Q2 2026 | $343M | +14% |
| Q1 2026 | $317M | +19% |
| Q4 2025 | $358M | +20% |
| Q3 2025 | $314M | +2.3% |
| Q2 2025 | $302M | +1% |
| Q1 2025 | $266M | -6.3% |
| Q4 2024 | $299M | +2% |
SUPN's revenue has grown year over year for six quarters in a row: $356M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 51% | +37 points |
| Q2 2026 | 47% | +23 points |
| Q1 2026 | 43% | +18 points |
| Q4 2025 | 23% | -9.5 points |
| Q3 2025 | 14% | +12 points |
| Q2 2025 | 24% | +63 points |
| Q1 2025 | 25% | -1.6 points |
| Q4 2024 | 32% | +11 points |
SUPN has the edge over NVO on profitability, with a higher operating margin.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
SUPN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $83M | +$142M |
| Q2 2026 | $222M | +57% |
| Q1 2026 | -$29M | -141% |
| Q4 2025 | -$245M | -$224M |
| Q3 2025 | -$59M | -$54M |
| Q2 2025 | $141M | +68% |
| Q1 2025 | $70M | +$110M |
| Q4 2024 | -$21M | +$278M |
SUPN has burned cash in most quarters: $31M over the past year, down 76% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SUPN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -2M shares |
| 1 year | -5.4% | -7M shares |
| 3 years | -11% | -15.7M shares |
SUPN has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $177M |
| Q1 2026 | $126M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $11M |
| Q4 2024 | $51M |
SUPN spent $303M buying back its own shares over the past year, about five times what it spent the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SUPN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.7x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | 0.5x | Very low |
SUPN has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SUPN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.4 | Neutral |
| Stochastic | 32.2 | Neutral |
SUPN's weekly RSI is 40 (neutral) and its Stochastic is 32 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SUPN PE vs Healthcare Sector
| Metric | SUPN | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 1 | 29 | 28 pts below |
SUPN has the edge over NVO on valuation relative to its sector.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SUPN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.3 | 19% below |
| 20 week MA | $37.3 | 22% below |
| 50 week MA | $35.8 | 18% below |
| 100 week MA | $26.3 | 11% above |
| 200 week MA | $21.9 | 34% above |
SUPN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
SUPN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.83 | $6.90 | +144% |
| 2021 | $6.90 | $17.8 | +157% |
| 2022 | $17.8 | $22.0 | +24% |
| 2023 | $22.0 | $15.3 | -31% |
| 2024 | $15.3 | $12.4 | -19% |
| 2025 | $12.4 | $36.2 | +192% |
| 2026 YTD | $36.2 | $29.2 | -19% |
SUPN has the edge over NVO on returns for 2026, with the stronger performance.